Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2011-03-08
2011-03-08
Saucier, Sandra (Department: 1651)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S009323, C977S905000
Reexamination Certificate
active
07901674
ABSTRACT:
Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the sane. The blood cells may be red blood cells or blood platelets.
REFERENCES:
patent: 5651966 (1997-07-01), Read et al.
patent: 5891393 (1999-04-01), Read et al.
patent: 5902608 (1999-05-01), Read et al.
patent: 5993804 (1999-11-01), Read et al.
patent: 6884573 (2005-04-01), Fischer et al.
patent: 2002/0009500 (2002-01-01), Wolkers et al.
patent: 2002/0114791 (2002-08-01), Crowe et al.
patent: 2003/0054330 (2003-03-01), Fischer et al.
patent: 2006/0270030 (2006-11-01), Voigt et al.
patent: 05126696 (1993-04-01), None
patent: 08-109142 (1996-04-01), None
patent: 2001333771 (2001-12-01), None
patent: WO 93/23997 (1993-12-01), None
patent: WO 99/34680 (1999-07-01), None
Examination Report, EP 04 801 949.1, European Patent Office, Nov. 13, 2008, 6 pp.
Freitas RA, Jr. Amorphous carbon particles. Nanomedicine, vol. IIA: Biocompatibility. Landes Bioscience, Georgetown, TX. 2003, Section 15.3.3.5, 6 pages.
Merricks et al., “Binding and internalization of fibrinogen and F-actin distribution in rehydrated, lyophilized platelets,” Blood 92(10) Supp. 1, part 1-2, 71B (1998).
Sanders, Jr. et al., “Fibrinogen Binding to Rehydrated Lyophilize(d) Platelet Surface GpIIb-IIIa: Normal Clot Formation and TPA Lysis,” Blood 88(10) Supp. 1, part 1-2 30A (1988).
Khandelwal et al.; “von Willebrand Factor Binding to Rehydrated Lyophilized Platelet Surface GPIb and Inhibition by Monoclonal Antibody to GPIb”Abstract Only. The FASEB Journal, 11, abstract #1812, p. A312 (1997).
Arroyo et al.; In Vivo Photoactivation of Caged-ThrombinThromb Haemost78 791-793 (1997).
Artemov, Dmitri; “Molecular Magnetic Resonance Imaging with Targeted Contrast Agents”Journal of Cellular Biochemistry90 518-524 (2003).
Bode et al.; “Activation and adherence of lyophilized human platelets on canine vessel strips in the Baumgartner perfusion chamber”J. Lab. Clin. Med. 133:2 200-211 (1999).
Chaterjee et al.; “Size dependent magnetic properties of iron oxide nanoparticles”Journal of Magnetism and Magnetic Materials257 113-118 (2003).
Chu et al.; “Derivatization of unprotected polynucleotides”Nucleic Acids Research11:18 6513-6529 (1983).
Crotty et al.; “Ribavirin's antiviral mechanism of action; lethal mutagenesis?”J. Mol. Med. 80 86-95 (2002).
DiStefano et al.; “Liver Glycotargeting of Antiviral Nucleoside Analogues”Trends in Glycosci. and Glycotech. 50 461-472 (1997).
Douri et al.; “Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery”Blood Coagulation and Fibrinolysis11:supp 1 S121-S127 (2000).
Dutton et al.; “Recombinant Factor VIIa for Control of Hemorrhage: Early Experience in Critically Ill Trauma Patients”Journal of Clinical Anesthesia15 184-188 (2003).
Fischer et al.; “Intracellular function in rehydrated lyophilized platelets”British Journal of Haematology111 167-174 (2000).
Fischer et al.; “Splenic Clearance Mechanisms of Rehydrated, Lyophilized Platelets”Art. Cells, Blood Subs., and Immob. Biotech. 29:6 439-451 (2001).
Flacke et al.; “Novel MRI Contrast Agent for Molecular Imaging of Fibrin Implications for Detecting Vulnerable Plaques”Circulation104 1280-1285 (2001).
Hedner et al.; “Management of Hemophilia Patients with Inhibitors”Hematology/Oncology Clinics of North America6:5 1035-1046 (1992).
Kristensen et al.; “Clinical Experience with Recombinant Factor VIIa in Patients with Thrombocytopenia”Haemostasis26:supp. 1 159-164 (1996).
Monahan et al.; “Adeno-associated virus vectors for gene therapy: more pros than cons?”Molecular Medicine Today6 433-440 (2000).
Monroe et al.; “Platelet activity of high-dose factor VIIa is independent of tissue factor”British Journal of Haematology99 542-547 (1997).
Monroe et al.; “The Factor VII-Platelet Interplay: Effectiveness of Recombinant Factor VIIa in the Treatment of Bleeding in Severe Thrombocytopathia”Seminars in Thrombosis and Hemostasis26:4 (2000).
Nichols et al.; “Porcine von Willebrand Disease and Atherosclerosis”American Journal of Pathology140:2 403-415 (1992).
Pankhurst et al.; “Applications of magnetic nanoparticles in biomedicine”Journal of Physics D: Applied Physics36 R167-R181 (2003).
Poon et al.; “Recombinant activated factor VII (NovoSeven®) treatment of platelet-related bleeding disorders”Blood Coagulation and Fibrinolysis11:supp 1 S55-S68 (2000).
Read et al.; “Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: Potential for long-term storage of dried platelets for transfusion”Proc. Natl. Acad. Sci. USA92 397-401 (1995).
Rofsky et al.; “MR Angiography in the Evaluation of Atherosclerotic Peripheral Vascular Disease”Radiology214:2 325-338 (2000).
Examiner's First Report on Patent Application AU 2004269308, IP Australia, Nov. 6, 2008, 3 pages.
Campbell et al. “A Novel Use of Rehydrated, Lyophilized Platelets Increases Recombinant FvIIa Procoagulant Activity in a Model of Hemophilia”Blood108(11) (p. 1 of 2) (Abstract Only) (2006) and48thAnnual Meeting of the American Society of Hematology, Orlando, FL, USA (2006).
Fraternale et al. “Role of Macrophage Protection on the Development of Murine AIDS”JAIDS Journal of Acquired Immune Deficiency Syndromes21:81-89 (1999).
Supplemental European Search Report for Application No. PCT/US2004015320; dated May 29, 2007.
Fraternale et al. Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model. Antiviral Research. 2002, vol. 56, pp. 263-272.
“Notification of the Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration” For International Application No. PCT/US04/15320, mailed Oct. 28, 2005.
Fischer Thomas
Nichols Timothy C.
Read Marjorie S.
Myers Bigel Sibley & Sajovec P.A.
Saucier Sandra
The University of North Carolina at Chapel Hill
LandOfFree
Aldehyde-fixed platelets with internalized paramagnetic or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aldehyde-fixed platelets with internalized paramagnetic or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aldehyde-fixed platelets with internalized paramagnetic or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2652123